News

Developed by discovered by D-Pharm, DP-VPA is a drug indicated for the treatment of patients who are suffering from epilepsy, migraine and bipolar disorder. As per the terms

In the trial, the drug was well tolerated at all the doses tested and has demonstrated preliminary evidence of efficacy. The trial investigated the safety, tolerability and efficacy

Earlier, the company has received orphan drug status for CYT387 for the treatment of myelofibrosis from the US Food and Drug Administration (FDA). YM BioSciences president and CEO

As per the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of US patent 7,935,528. The patent covers the methods

The patent entitled, ‘Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker" is still pending. Ventrus chairman and CEO Russell Ellison said this is a

Both the companies also signed a supply agreement with minimum purchase volumes which was scheduled over several years. According to Tecan, upon successful completion of development the sales

The project will be initiated in Q3 2011 and run for three years. The grant will cover up to 35% of the project costs. PCI Biotech is developing

Connell Brothers serves as a supplier and customers in industries, including animal feed, lube oils, adhesives, water treatment, textiles, ceramics, construction, food and beverage, personal care, rubber and

The company has reported net profit of INR430m, compared to INR590m during the same period last year. For FY 2010-11, sales increased 16% to INR21.61bn compared with INR18.67bn